Brokerages Anticipate Wave Life Sciences Ltd (NASDAQ:WVE) to Post -$1.39 Earnings Per Share
Wall Street analysts expect Wave Life Sciences Ltd (NASDAQ:WVE) to post earnings of ($1.39) per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Wave Life Sciences’ earnings. The lowest EPS estimate is ($1.50) and the highest is ($1.28). Wave Life Sciences posted earnings of ($1.28) per share during the same quarter last year, which suggests a negative year over year growth rate of 8.6%. The firm is scheduled to announce its next earnings results on Friday, November 8th.
According to Zacks, analysts expect that Wave Life Sciences will report full-year earnings of ($5.38) per share for the current fiscal year, with EPS estimates ranging from ($5.88) to ($5.01). For the next fiscal year, analysts expect that the company will post earnings of ($4.51) per share, with EPS estimates ranging from ($5.45) to ($3.32). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Wave Life Sciences.
Wave Life Sciences (NASDAQ:WVE) last posted its earnings results on Monday, July 29th. The company reported ($1.22) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.11) by ($0.11). Wave Life Sciences had a negative return on equity of 120.41% and a negative net margin of 861.41%. The company had revenue of $7.63 million during the quarter, compared to analyst estimates of $15.76 million.
In other Wave Life Sciences news, insider Michael A. Panzara sold 3,058 shares of the company’s stock in a transaction on Friday, July 5th. The stock was sold at an average price of $26.94, for a total value of $82,382.52. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 39.70% of the company’s stock.
Large investors have recently made changes to their positions in the business. BlackRock Inc. increased its stake in Wave Life Sciences by 6.7% during the 2nd quarter. BlackRock Inc. now owns 1,811,996 shares of the company’s stock worth $47,275,000 after acquiring an additional 113,292 shares during the period. Virtus ETF Advisers LLC increased its stake in shares of Wave Life Sciences by 93.3% in the 2nd quarter. Virtus ETF Advisers LLC now owns 10,387 shares of the company’s stock valued at $271,000 after purchasing an additional 5,014 shares during the last quarter. Athanor Capital LP bought a new position in shares of Wave Life Sciences in the 2nd quarter valued at $566,000. Northern Trust Corp increased its stake in shares of Wave Life Sciences by 2.0% in the 2nd quarter. Northern Trust Corp now owns 265,291 shares of the company’s stock valued at $6,922,000 after purchasing an additional 5,145 shares during the last quarter. Finally, Matisse Capital increased its stake in shares of Wave Life Sciences by 34.8% in the 2nd quarter. Matisse Capital now owns 60,826 shares of the company’s stock valued at $1,587,000 after purchasing an additional 15,715 shares during the last quarter. Hedge funds and other institutional investors own 86.28% of the company’s stock.
WVE traded down $0.31 on Wednesday, hitting $21.06. The company had a trading volume of 2,207 shares, compared to its average volume of 387,548. The stock’s fifty day simple moving average is $23.56. Wave Life Sciences has a 1-year low of $18.16 and a 1-year high of $56.00. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.33 and a current ratio of 2.33. The company has a market capitalization of $731.89 million, a PE ratio of -4.15 and a beta of 0.81.
About Wave Life Sciences
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Further Reading: Why Dividend Stocks May Be Right for You
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.